Citius Pharmaceuticals 관리

관리 기준 확인 2/4

Citius Pharmaceuticals CEO는 Leonard Mazur, Mar2016 에 임명되었습니다 의 임기는 8.75 년입니다. 총 연간 보상은 $ 1.98M, 24% 로 구성됩니다. 24% 급여 및 76% 보너스(회사 주식 및 옵션 포함). 는 € 51.42K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 51.42K. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 8.6 년입니다.

주요 정보

Leonard Mazur

최고 경영자

US$2.0m

총 보상

CEO 급여 비율	24.0%
CEO 임기	8.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	3.9yrs
이사회 평균 재임 기간	8.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Leonard Mazur 의 보수는 Citius Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$38m
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	US$2m	US$475k	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$28m
Sep 30 2022	US$1m	US$400k	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	n/a	n/a	-US$26m
Sep 30 2021	US$788k	US$348k	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	n/a	n/a	-US$21m
Sep 30 2020	US$550k	US$250k	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	n/a	n/a	-US$16m
Sep 30 2019	US$473k	US$250k	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$13m
Sep 30 2018	US$398k	US$250k	-US$13m

보상 대 시장: Leonard 의 총 보상 ($USD 1.98M )은 German 시장( $USD 469.88K ).

보상과 수익: 회사가 수익성이 없는 동안 Leonard 의 보상이 증가했습니다.

CEO

Leonard Mazur (79 yo)

8.8yrs

테뉴어

US$1,981,113

보상

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Leonard Mazur	Co-Founder	8.8yrs	US$1.98m	0.19% € 51.4k
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.2yrs	US$1.59m	1.03% € 281.3k
Myron Czuczman	Executive VP & Chief Medical Officer	4.4yrs	US$1.17m	0% € 0
Jaime Bartushak	Chief Business Officer	7.1yrs	US$809.00k	0.031% € 8.5k
Gary Talarico	Executive Vice President of Operations	8.8yrs	데이터 없음	데이터 없음
Ilanit Allen	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Alan Lader	Senior VP and Head of Clinical Operations & Quality Assurance	2.8yrs	데이터 없음	데이터 없음
Dhananjay Wadekar	Senior Vice President of Business Strategy	3.9yrs	데이터 없음	데이터 없음
Kelly Creighton	Executive Vice President of Chemistry	3.1yrs	데이터 없음	데이터 없음
Nikolas Burlew	Executive Vice President of Quality Assurance	1.9yrs	데이터 없음	데이터 없음
Catherine Kessler	Executive Vice President of Regulatory Affairs	1.3yrs	데이터 없음	데이터 없음

3.9yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 관리: 47N0 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Leonard Mazur	Co-Founder	10.3yrs	US$1.98m	0.19% € 51.4k
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.2yrs	US$1.59m	1.03% € 281.3k
Dennis McGrath	Independent Director	1.8yrs	US$150.13k	0% € 0
Michael Matthay	ARDS Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Suren Dutia	Independent Director	9.2yrs	US$196.97k	0% € 0
Carol Webb	Independent Director	8.8yrs	US$190.97k	0.0061% € 1.7k
Eugene Holuka	Independent Director	8.5yrs	US$190.97k	0.0012% € 335.5
Issam Raad	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mark Rupp	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leonard Mermel	Member of Scientific Advisory Board	6.4yrs	데이터 없음	데이터 없음
John Laffey	ARDS Scientific Advisory Board Member	3.5yrs	데이터 없음	데이터 없음
Lorraine Ware	ARDS Scientific Advisory Board Member	no data	데이터 없음	데이터 없음

8.6yrs

평균 재임 기간

77yo

평균 연령

경험이 풍부한 이사회: 47N0 의 이사회는 경험(평균 재직 기간 8.6 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/29 18:50
장 마감 주가	2024/11/25 00:00
수익	2024/09/30
연간 수익	2024/09/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Citius Pharmaceuticals, Inc. 4 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jason Kolbert	D. Boral Capital LLC.
Jason Kolbert	H.C. Wainwright & Co.
Vernon Bernardino	H.C. Wainwright & Co.

Citius Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Insufficient new directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Insufficient new directors

Recent updates

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Forecast breakeven date pushed back to 2026

Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

New major risk - Financial position

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Insufficient new directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Insufficient new directors

Insufficient new directors

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Insufficient new directors

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Insufficient new directors

Insufficient new directors

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Forecast to breakeven in 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $76.500002 million.

New 90-day high: €1.69

Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies At the Virtual Investor Conferences Small and Microcap Showcase on February 4

Citius Pharmaceuticals, Inc. announced that it has received $20.000012 million in funding

Citius Pharmaceuticals, Inc. announced that it expects to receive $20.000012 million in funding

New 90-day high: €1.01

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 09, 2021

Citius Pharmaceuticals, Inc.'s Mino-Lok Trial Sites Resupplied with Registration Batch Product

Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial

New 90-day low - €0.72

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.363044 million.

New 90-day high - €1.29

Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

CEO 보상 분석

CEO